International Headache Society

To advance headache science, education & treatment. Our Journal: @JCephalalgia. Find us on

[International Headache Society @ihs_official]

Sunday Quiz for #MigraineAwarenessMonth

According to ICHD-3, which of the following is NOT included as an “episodic syndrome that may be associated with migraine”?

A. Cyclical vomiting syndrome
B. Benign paroxysmal vertigo
C. Benign paroxysmal positional vertigo
D. Benign paroxysmal torticollis

#migraine #headache #sundayquiz

[International Headache Society @ihs_official]

New in Cephalalgia Reports!
The real-world INFUSE study is evaluating the effectiveness of IV eptinezumab for the preventive treatment of migraine in participants in whom ≥1 CGRP-targeted preventive therapy had previously failed
•
Switching to eptinezumab treatment was associated with reduced migraine burden and improvements in multiple participant-reported migraine outcomes, including headache frequency, disability, disease status, and brain fog, despite substantial baseline disease burden.

https://t.co/dTV1tp6cU6
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

New in Cephalalgia Reports!
In this 11-country MENA study (n = 2904 students), 78.6% reported headache during or after screen exposure.
•
Screen use ≥7 h/day and continuous use >2 h without breaks independently increased headache odds.
•
Caffeine, poor hydration, variable sleep, and high stress were significantly associated with screen-related headache.
•
Female sex and family migraine history increased reporting likelihood.
•
Findings suggest modifiable behavioral and ergonomic targets for prevention in academic settings.

https://t.co/PBrH1s6Co9
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

For #MigraineAwarenessMonth, we are pleased to share this fantastic video message from Professor Aynur Özge.

Migraine is more than “just a headache.” Greater awareness, understanding, and education are essential to improving care and reducing the burden for people living with migraine worldwide.

@ozge.aynur @IHS_Official
#Migraine #MigraineAwareness #MigraineAwarenessMonth #HeadacheMedicine

[International Headache Society @ihs_official]

New in Cephalalgia!
Misdiagnosis is common in migraine—28% were wrongly diagnosed with conditions like sinusitis or cervical issues. Resistant/refractory cases had more testing, but not more misdiagnoses. Timely and accurate diagnosis is needed.
https://t.co/VXpAvLxir9
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

New in Cephalalgia!
This study is the first to test the diagnostic performance of the most commonly used diagnostic criteria for Burning mouth syndrome and provides the first data-driven set of diagnostic criteria for the condition.
https://t.co/OTIWE8UvUg
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

We are delighted to announce that Cephalalgia’s impact factor has increased to 5.8.
The journal has remained in Q1 for decades and continues to rank strongly at 29 out of 296 in Clinical Neurology and 55 out of 330 in Neuroscience.

This milestone reflects the dedication of our authors, reviewers, and editorial community. Thank you to everyone contributing to the ongoing success of the journal.
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

Happening tomorrow!

Cluster headache remains one of the most disabling and under-recognised neurological disorders, yet research in the field is advancing rapidly.

Join the upcoming International Headache Society (IHS) Cluster Headache Webinar: Updates in Cluster Headache, featuring experts from the IHS Cluster Headache Special Interest Group discussing the latest developments in:

🔹 Pathogenesis of cluster headache
🔹 Preventive treatment updates
🔹 Acute treatment advances
🔹 The emerging role of gepants as a potential preventive option

A fantastic opportunity for clinicians, researchers, trainees, and anyone interested in headache medicine to hear from leading international experts and engage in discussion during the live Q&A session.

📅 Thursday 18 June
🕐 13:00 BST | 14:00 CEST | 08:00 EST

Speakers:
• Dr Mona Nada (Chair)
• Dr Rolf Fronczek
• Dr Nunu Lund
• Dr Mark Burish
• Dr Soo-Jin Cho

Looking forward to an exciting discussion on the future of cluster headache research and care.
Link to register:
https://t.co/Ro6SnosLpU
#ClusterHeadache #HeadacheMedicine #Neurology #HeadacheResearch #IHSHeadache #MigraineAndHeadache #ClinicalResearch #NeurologyEducation

[International Headache Society @ihs_official]

New in Cephalalgia!
A ≥50% reduction in monthly migraine days (MMDs) does not always reflect meaningful clinical benefit, as most patients who met this threshold did not achieve IHS-aspired optimal migraine control with <4 MMDs.
https://t.co/fk9TX3Yq0c
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

New in Cephalalgia!
Severity of dependence on analgesics in patients with medication-overuse headache (MOH) is strongly associated with headache burden, nicotine dependence, psychological distress, and addiction-related personality traits.
https://t.co/4ytvrBwtPh
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

New in Cephalalgia!
Specific subgroups of individuals with migraine may respond better to biofeedback (i.e., improvements in Migraine-Specific Quality of Life Role Function Restrictive (MSQv2.1-RFR)) based on baseline characteristics (i.e.,mindfulness traits and interest in physical exercise).
https://t.co/aOR5oZOZu0
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

New in Cephalalgia!
In real-world practice, CGRP monoclonal antibodies substantially reduce migraine frequency, but achieving optimal migraine control remains challenging, particularly in patients with higher baseline migraine burden.
https://t.co/NcGeH19xRP
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

New in Cephalalgia Reports!
Omega-3 supplements reduce migraine frequency and disability in adults. Optimal effects occur with moderate doses (≈2–2.5 g/day) in episodic migraine, while structured diet in chronic migraine.
https://t.co/ggOocPfbju
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

New in Cephalalgia!
This systematic review and meta-analysis provide robust evidence on the effect of angiotensin II receptor blockers (ARBs), particularly candesartan, in the prevention of episodic migraine, supporting the rationale for reconsidering its position in international guidelines.
https://t.co/0YvtpwOoh3
#migraine #headache #brain #pain #neurology #neuroscience

[International Headache Society @ihs_official]

Applications are now open for the 2026–2027 Cephalalgia Reviewer Academy! 🧠📚

A unique mentored training programme by Cephalalgia and Cephalalgia Reports, designed to support the next generation of expert peer reviewers in headache research.

✅ Structured peer-review training
✅ Mentorship and supervised practice
✅ Formal certification
✅ Open to researchers and healthcare professionals
✅ No age limit

📅 Deadline: 14 June 2026

A great opportunity to develop your peer-review skills, strengthen headache research, and contribute to the scientific community.

🔗 Apply now / More information: https://t.co/0DkS9KECPZ
#Cephalalgia #HeadacheResearch #Migraine #PeerReview #Neurology #HeadacheMedicine #AcademicMedicine #EarlyCareerResearchers

[International Headache Society @ihs_official]

📢 Welcoming our new Associate Editor!

We are delighted to welcome Prof. Zhao Dong as the newest Associate Editor for *Cephalalgia* and *Cephalalgia Reports*.

Prof. Dong's expertise and contributions to headache medicine will be a valuable addition to our editorial team. We look forward to working together to advance high-quality research and support the global headache community.

Please join us in welcoming Prof. Dong to the editorial board.

#Cephalalgia #CephalalgiaReports #HeadacheResearch #MigraineResearch #Neurology #ScientificPublishing #HeadacheMedicine

[International Headache Society @ihs_official]

Cluster headache remains one of the most disabling and under-recognised neurological disorders, yet research in the field is advancing rapidly.

Join the upcoming International Headache Society (IHS) Cluster Headache Webinar: **Updates in Cluster Headache**, featuring experts from the IHS Cluster Headache Special Interest Group discussing the latest developments in:

🔹 Pathogenesis of cluster headache
🔹 Preventive treatment updates
🔹 Acute treatment advances
🔹 The emerging role of gepants as a potential preventive option

A fantastic opportunity for clinicians, researchers, trainees, and anyone interested in headache medicine to hear from leading international experts and engage in discussion during the live Q&A session.

📅 Thursday 18 June
🕐 13:00 BST | 14:00 CEST | 08:00 EST

Speakers:
• Dr Mona Nada (Chair)
• Dr Rolf Fronczek
• Dr Nunu Lund
• Dr Mark Burish
• Dr Soo-Jin Cho

Looking forward to an exciting discussion on the future of cluster headache research and care.
Link to register:
https://t.co/Ro6SnosLpU
#ClusterHeadache #HeadacheMedicine #Neurology #HeadacheResearch #IHSHeadache #MigraineAndHeadache #ClinicalResearch #NeurologyEducation

[Cephalalgia @JCephalalgia]

A message from Prof. Simona Sacco, Editor-in-Chief of Cephalalgia and Cephalalgia Reports, for Migraine Awareness Month.

It is time for action.

#MigraineAwareness #Migraine #HeadacheDisorders #Cephalalgia #MigraineResearch

[International Headache Society @ihs_official]

Applications are now open for the 2026–2027 Cephalalgia Reviewer Academy! 🧠📚

A unique mentored training programme by Cephalalgia and Cephalalgia Reports, designed to support the next generation of expert peer reviewers in headache research.

✅ Structured peer-review training
✅ Mentorship and supervised practice
✅ Formal certification
✅ Open to researchers and healthcare professionals
✅ No age limit

📅 Deadline: 14 June 2026

A great opportunity to develop your peer-review skills, strengthen headache research, and contribute to the scientific community.

🔗 Apply now / More information: https://t.co/0DkS9KECPZ
#Cephalalgia #HeadacheResearch #Migraine #PeerReview #Neurology #HeadacheMedicine #AcademicMedicine #EarlyCareerResearchers

[International Headache Society @ihs_official]

#Migraine Awareness Month #Inspirational Interview with Spectacular @HeadacheMD Dr. Tesha Monteith @JCephalalgia @IHS_Official @NinaRiggins

https://t.co/VYjJnejPHM